Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 13/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.69 |
| ▸ | USP2 | O75604 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | USP1 | O94782 | 1/20 | 0.55 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212154 | 0.85 | HDAC1 (0.64) | CLK4DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1065202 | 0.83 | HDAC3 (0.74) | CLK4DYRK1ACYP3A4HDAC1NCOR2 | |
| SCHEMBL14554959 | 0.82 | CLK4 (1.00) | CLK4DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL211002 | 0.79 | HDAC1 (1.00) | CLK4DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL210701 | 0.77 | CLK4 (0.50) | CLK4DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10272801 | 0.77 | CA1 (0.50) | CLK4DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16264679 | 0.77 | ALDH1A1 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19HDAC1 | |
| SCHEMBL15761769 | 0.77 | RAB9A (0.62) | USP2HSD17B10ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL211587 | 0.77 | ALDH1A1 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C19HDAC1 | |
| SCHEMBL28884649 | 0.76 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CLK4 2550/4885DYRK1A 3424/4885CYP1A2 4230/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | CLK4 2700/4885DYRK1A 3550/4885CYP1A2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.